<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:sbh="https://wiki.synbiohub.org/wiki/Terms/synbiohub#" xmlns:sbol="http://sbols.org/v2#" xmlns:ns0="http://www.w3.org/ns/prov#" xmlns:ns1="http://purl.org/dc/elements/1.1/" xmlns:ns2="http://purl.org/dc/terms/" xmlns:ns3="http://purl.obolibrary.org/obo/">
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00113_1_sequence/1">
    <sbol:elements>tggggactttccgctggggactttccgctggggactttccgctggggactttccgctggggactttccgc</sbol:elements>
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00113_1_sequence"/>
    <sbol:version>1</sbol:version>
    <sbol:displayId>sb8b00113_1_sequence</sbol:displayId>
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
  </sbol:Sequence>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00113_1_comp/1">
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00113/suppl/sb-2018-00113a_si_001.pdf"/>
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00113_1_comp"/>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
    <sbol:version>1</sbol:version>
    <sbol:displayId>sb8b00113_1_comp</sbol:displayId>
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00113"/>
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00113_1_sequence/1"/>
  </sbol:ComponentDefinition>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00113_4_comp/1">
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00113"/>
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
    <sbol:version>1</sbol:version>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00113_4_comp"/>
    <sbol:displayId>sb8b00113_4_comp</sbol:displayId>
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00113_4_sequence/1"/>
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00113/suppl/sb-2018-00113a_si_001.pdf"/>
  </sbol:ComponentDefinition>
  <sbol:Collection rdf:about="http://examples.org/sb8b00113/1">
    <ns1:subject>rheumatoid arthritis</ns1:subject>
    <ns1:subject>eYFP</ns1:subject>
    <ns2:references>Bolon, B., Campagnuolo, G., Zhu, L., Duryea, D., Zack, D., Feige, U. Interleukin-1beta and tumor necrosis factor-alpha produce distinct, time-dependent patterns of acute arthritis in the rat knee Vet. Pathol. 2004. 41:235-43.</ns2:references>
    <ns1:subject>IL-4</ns1:subject>
    <ns1:subject>-1</ns1:subject>
    <ns1:subject>p50</ns1:subject>
    <ns2:references>Henderson, B., Pettipher, E. R. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo Clin. Exp. Immunol. 1989. 75:306-10.</ns2:references>
    <ns1:subject>anakinra</ns1:subject>
    <ns1:subject>NF-&#954;B</ns1:subject>
    <ns1:subject>Anakinra</ns1:subject>
    <ns1:subject>IkBa</ns1:subject>
    <ns2:references>Lam, D., Harris, D., Qin, Z. Inflammatory mediator profiling reveals immune properties of chemotactic gradients and macrophage mediator production inhibition during thioglycollate elicited peritoneal inflammation Mediators Inflammation 2013. 2013.</ns2:references>
    <ns2:dateAccepted>2018-10-25</ns2:dateAccepted>
    <ns2:references>Vegas, A. J., Veiseh, O., Gu&#776;rtler, M., Millman, J. R., Pagliuca, F. W., Bader, A. R., Doloff, J. C., Li, J., Chen, M., Olejnik, K., Tam, H. H., Jhunjhunwala, S., Langan, E., Aresta-Dasilva, S., Gandham, S., McGarrigle, J. J., Bochenek, M. A., Hollister-Lock, J., Oberholzer, J., Greiner, D. L., Weir, G. C., Melton, D. A. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice Nat. Med. 2016. 22:306-11.</ns2:references>
    <ns2:references>Mease, P. J. Adalimumab in the treatment of arthritis Therapeutics and Clinical Risk Management 2007. 3:133-148.</ns2:references>
    <ns1:subject>EDTA</ns1:subject>
    <ns1:subject>IKK</ns1:subject>
    <ns1:subject>cyclinD1</ns1:subject>
    <ns1:subject>Adalimumab</ns1:subject>
    <ns2:references>Emery, P. Treatment of rheumatoid arthritis BMJ: British Medical Journal 2006. 332:152-155.</ns2:references>
    <ns1:subject>NF-&#954;B transcription factor</ns1:subject>
    <ns1:subject>Lines</ns1:subject>
    <ns2:references>Haraoui, B., Bykerk, V. Etanercept in the treatment of rheumatoid arthritis Therapeutics and Clinical Risk Management 2007. 3:99-105.</ns2:references>
    <ns2:type rdf:resource="http://purl.org/dc/dcmitype/Text"/>
    <ns1:subject>CaCl</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00113_1_sequence/1"/>
    <ns1:subject>cells</ns1:subject>
    <ns1:subject>thioglycollate</ns1:subject>
    <ns1:subject>TNF&#945;</ns1:subject>
    <ns1:subject>Thioglycate</ns1:subject>
    <ns1:subject>IL-17a</ns1:subject>
    <ns1:subject>Etanercept</ns1:subject>
    <ns1:subject>designer cell</ns1:subject>
    <ns1:subject>human</ns1:subject>
    <ns1:subject>Cells</ns1:subject>
    <ns1:subject>mice</ns1:subject>
    <ns3:OBI_0001617>30358982</ns3:OBI_0001617>
    <ns1:subject>-GpL</ns1:subject>
    <ns1:subject>cyclosporine</ns1:subject>
    <ns1:subject>alginate-</ns1:subject>
    <ns2:references>Counter, C. M., Hahn, W. C., Wei, W., Caddle, S. D., Beijersbergen, R. L., Lansdorp, P. M., Sedivy, J. M., Weinberg, R. A. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization Proc. Natl. Acad. Sci. U. S. A. 1998. 95:14723-14728.</ns2:references>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00113_2_comp/1"/>
    <ns1:subject>htnfa-mab1</ns1:subject>
    <ns2:references>Du, R., Zhao, H., Yan, F., Li, H. IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells J. Leukocyte Biol. 2014. 96:39-48.</ns2:references>
    <ns1:subject>synthetic biology</ns1:subject>
    <ns2:references>Rosman, Z., Shoenfeld, Y., Zandman-Goddard, G. Biologic therapy for autoimmune diseases: an update BMC Med. 2013. 11.</ns2:references>
    <ns1:subject>I&#954;B kinase-2</ns1:subject>
    <ns1:subject>red fluorescent protein</ns1:subject>
    <ns1:subject>IL-1 receptor antagonist</ns1:subject>
    <ns1:subject>closed-loop systems</ns1:subject>
    <ns1:subject>alginate</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00113_3_sequence/1"/>
    <ns2:references>Magdolen, U., Schmitt, M., Hildebrandt, B., Diehl, P., Schauwecker, J., Saldamli, B., Burgkart, R., Tu&#776;bel, J., Gradinger, R., Royer-Pokora, B. Spontaneous in vitro transformation of primary human osteoblast-like cells Cancer Genomics Proteomics 2010. 7:61-6.</ns2:references>
    <ns1:subject>Ca 2+</ns1:subject>
    <ns2:references>Sharma, R.
R., Pollock, K., Hubel, A., McKenna, D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices Transfusion 2014. 54:1418-37.</ns2:references>
    <ns1:subject>insulin</ns1:subject>
    <ns1:subject>IL17a</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00113_1_comp/1"/>
    <ns1:subject>HEK293T</ns1:subject>
    <ns2:references>Badr, C., Niers, J. M., Tjon-Kon-Fat, L. A., Noske, D. P., Wurdinger, T., Tannous, B. A. Real-time monitoring of NF-kappaB activity in cultured cells and in animal models Mol. Imaging 2009. 8:278-290.</ns2:references>
    <ns1:subject>tumor necrosis factor receptor 2</ns1:subject>
    <ns1:subject>FOXP3</ns1:subject>
    <ns1:subject>cytokines</ns1:subject>
    <ns1:creator>Dennis Hell</ns1:creator>
    <ns1:subject>IKK complex</ns1:subject>
    <ns1:subject>hIL-2</ns1:subject>
    <ns1:subject>sIL6R</ns1:subject>
    <ns2:title>Self-Adjusting Cytokine Neutralizer Cells as a Closed-Loop Delivery System of Anti-Inflammatory Biologicals</ns2:title>
    <ns2:references>Ruder, W. C., Lu, T., Collins, J. J. Synthetic biology moving into the clinic Science 2011. 333:1248-1252.</ns2:references>
    <ns2:dateSubmitted>2018-03-15</ns2:dateSubmitted>
    <ns2:references>Lang, I., Fu&#776;llsack, S., Wyzgol, A., Fick, A., Trebing, J., Arana, J. A., Scha&#776;fer, V., Weisenberger, D., Wajant, H. Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells J. Biol. Chem. 2016. 291:5022-37.</ns2:references>
    <ns1:subject>antitranscription factor</ns1:subject>
    <ns1:subject>p-Nitrophenyl Phosphate</ns1:subject>
    <ns2:abstract>The cytokines tumor necrosis factor &#945; (TNF&#945;) and interleukin 1 &#946; (IL-1&#946;) are both strong NF-&#954;B activators and some of the first cytokines to be released in an inflammatory process. TNF&#945; and IL-1&#946; are present in many autoimmune diseases, such as rheumatoid arthritis (RA). TNF&#945; and IL-1&#946;-blocking therapies are quite successful and established in the treatment of RA, but may also be promising in other diseases. For the treatment of recurring autoimmune diseases, strong controlled sensor-effector cells inhibiting TNF&#945; or IL-1&#946; appear highly predestined. Such cells detect a disease biomarker and autonomously react with the dose-dependent production of therapeutic proteins. Hence, we aim to harness and assemble the interactions of TNF&#945;, IL-1&#946;, and NF-&#954;B, which are an ideal match for synthetic biology-based circuits to rewire the transmission to approved TNF&#945;- or IL-1&#946;-blocking biologicals. Considering the high impact of environmental influences on the dynamics of cell-based systems, we established closed-loop controllable cytokine neutralizer cells, monitoring cytokine levels and autonomously delivering powerful biologicals. This real-time processing system may provide dose-dependent drug delivery, which may be tailored for prospective cell and gene therapies against RA, and may offer a more personalized medicine than calculated drug dosing based on body weight.</ns2:abstract>
    <ns1:subject>Scheme</ns1:subject>
    <ns1:subject>etanercept</ns1:subject>
    <ns1:subject>hseap</ns1:subject>
    <ns1:subject>SEAP</ns1:subject>
    <ns1:subject>Foxp3</ns1:subject>
    <ns1:subject>GPL</ns1:subject>
    <ns1:subject>IgG</ns1:subject>
    <ns1:subject>I&#954;Ba</ns1:subject>
    <ns2:references>van
de Loo, A. A., van den Berg, W. B. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation Ann. Rheum. Dis. 1990. 49:238-45.</ns2:references>
    <ns1:subject>luciferase</ns1:subject>
    <ns1:subject>IL1RA</ns1:subject>
    <ns1:subject>pDH1</ns1:subject>
    <ns1:subject>HEK293T cells</ns1:subject>
    <ns1:subject>IL-2</ns1:subject>
    <ns2:references>Yao, Z., Painter, S. L., Fanslow, W. C., Ulrich, D., Macduff, B. M., Spriggs, M. K., Armitage, R. J. Human IL-17: a novel cytokine derived from T cells J. Immunol 1995. 155:5483-6.</ns2:references>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00113_3_comp/1"/>
    <ns1:subject>sIL-6R</ns1:subject>
    <ns2:references>Ali, T., Kaitha, S., Mahmood, S., Ftesi, A., Stone, J., Bronze, M. S. Clinical use of anti-TNF therapy and increased risk of infections Drug, Healthcare Patient Saf. 2013. 5:79-99.</ns2:references>
    <ns1:subject>TNFR2</ns1:subject>
    <ns1:subject>hIL-17a</ns1:subject>
    <ns1:subject>GpL</ns1:subject>
    <ns2:references>Xie, M., Ye, H., Wang, H., Charpin-El Hamri, G., Lormeau, C., Saxena, P., Stelling, J., Fussenegger, M. &#946;-cell-mimetic designer cells provide closed-loop glycemic control Science 2016. 354:1296-1301.</ns2:references>
    <ns1:subject>IL-1&#946;</ns1:subject>
    <ns2:references>Wajant, H., Pfizenmaier, K., Scheurich, P. Tumor necrosis factor signaling Cell Death Differ. 2003. 10:45-65.</ns2:references>
    <ns1:subject>hTNF&#945;</ns1:subject>
    <ns1:subject>IL6</ns1:subject>
    <ns1:subject>IL2</ns1:subject>
    <ns1:subject>CRL-11268</ns1:subject>
    <ns1:subject>Luciferase</ns1:subject>
    <ns1:subject>methotrexate</ns1:subject>
    <ns1:subject>RFP</ns1:subject>
    <ns1:subject>cytokines tumor necrosis factor &#945;</ns1:subject>
    <ns1:subject>FOXP3.37</ns1:subject>
    <ns1:subject>interleukin 1 &#946;</ns1:subject>
    <ns1:subject>Trypsin</ns1:subject>
    <ns1:subject>human HEK293T cells</ns1:subject>
    <ns1:subject>T75</ns1:subject>
    <ns1:subject>hIL-1&#946;</ns1:subject>
    <ns1:subject>lipopolysaccharide</ns1:subject>
    <ns0:wasDerivedFrom rdf:resource="https://pubs.acs.org/doi/10.1021/acssynbio.8b00113"/>
    <ns1:subject>mammalian cell lines</ns1:subject>
    <ns1:subject>princeps</ns1:subject>
    <ns2:references>McInnes, I. B., Schett, G. The pathogenesis of rheumatoid arthritis N. Engl. J. Med. 2011. 365:2205-19.</ns2:references>
    <ns1:subject>IL-10</ns1:subject>
    <ns2:description>The cytokines tumor necrosis factor &#945; (TNF&#945;) and interleukin 1 &#946; (IL-1&#946;) are both strong NF-&#954;B activators and some of the first cytokines to be released in an inflammatory process. TNF&#945; and IL-1&#946; are present in many autoimmune diseases, such as rheumatoid arthritis (RA). TNF&#945; and IL-1&#946;-blocking therapies are quite successful and established in the treatment of RA, but may also be promising in other diseases. For the treatment of recurring autoimmune diseases, strong controlled sensor-effector cells inhibiting TNF&#945; or IL-1&#946; appear highly predestined. Such cells detect a disease biomarker and autonomously react with the dose-dependent production of therapeutic proteins. Hence, we aim to harness and assemble the interactions of TNF&#945;, IL-1&#946;, and NF-&#954;B, which are an ideal match for synthetic biology-based circuits to rewire the transmission to approved TNF&#945;- or IL-1&#946;-blocking biologicals. Considering the high impact of environmental influences on the dynamics of cell-based systems, we established closed-loop controllable cytokine neutralizer cells, monitoring cytokine levels and autonomously delivering powerful biologicals. This real-time processing system may provide dose-dependent drug delivery, which may be tailored for prospective cell and gene therapies against RA, and may offer a more personalized medicine than calculated drug dosing based on body weight.</ns2:description>
    <ns1:subject>GFP</ns1:subject>
    <ns1:subject>hIL-6</ns1:subject>
    <ns2:references>Schukur, L., Geering, B., Charpin-El
Hamri, G., Fussenegger, M. Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis Sci. Transl. Med. 2015. 7.</ns2:references>
    <ns2:references>Lubberts, E. , and van den Berg, W. B. (2000&#8211;2013) Cytokines in the Pathogenesis of Rheumatoid Arthritis and Collagen-Induced Arthritis. In Madame Curie Bioscience Database, Landes Bioscience, Austin, TX, https://www.ncbi.nlm.nih.gov/books/NBK6288/.</ns2:references>
    <ns1:subject>IL-1RA</ns1:subject>
    <ns1:subject>autoimmune disease</ns1:subject>
    <ns1:subject>TNF&#945; (3)</ns1:subject>
    <ns1:subject>adalimumab</ns1:subject>
    <ns2:dateCopyrighted>2018</ns2:dateCopyrighted>
    <ns1:subject>ATCC</ns1:subject>
    <ns2:references>Aubin, F., Carbonnel, F., Wendling, D. The complexity of adverse side-effects to biological agents J. Crohns Colitis 2013. 7:257-62.</ns2:references>
    <ns1:subject>interceptions</ns1:subject>
    <ns1:subject>neutralizer cells</ns1:subject>
    <ns1:subject>NF&#954;B</ns1:subject>
    <ns2:references>Podolin, P. L., Callahan, J. F., Bolognese, B. J., Li, Y. H., Carlson, K., Davis, T. G., Mellor, G. W., Evans, C., Roshak, A. K. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1&#173;(2-[(aminocarbonyl)&#173;amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation J. Pharmacol. Exp. Ther. 2005. 312:373-81.</ns2:references>
    <ns2:references>Maitra, A., Arking, D. E., Shivapurkar, N., Ikeda, M., Stastny, V., Kassauei, K., Sui, G., Cutler, D. J., Liu, Y., Brimble, S. N., Noaksson, K., Hyllner, J., Schulz, T. C., Zeng, X., Freed, W. J., Crook, J., Abraham, S., Colman, A., Sartipy, P., Matsui, S., Carpenter, M., Gazdar, A. F. Genomic alterations in cultured human embryonic stem cells Nat. Genet. 2005. 37:1099-103.</ns2:references>
    <ns1:subject>Cytokine</ns1:subject>
    <ns2:isPartOf>ACS Synthetic
Biology</ns2:isPartOf>
    <ns1:subject>suppressor cells</ns1:subject>
    <ns2:references>Schiff, M. H., DiVittorio, G., Tesser, J., Fleischmann, R., Schechtman, J., Hartman, S., Liu, T., Solinger, A. M. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions Arthritis Rheum. 2004. 50:1752-60.</ns2:references>
    <ns1:subject>pDH40</ns1:subject>
    <ns2:references>Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, J. J., Garrone, P., Garcia, E., Saeland, S., Blanchard, D., Gaillard, C., Das Mahapatra, B., Rouvier, E., Golstein, P., Banchereau, J., Lebecque, S. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines J. Exp. Med. 1996. 183:2593-603.</ns2:references>
    <ns2:references>Wildner, G., Kaufmann, U. What causes relapses of autoimmune diseases? The etiological role of autoreactive T cells Autoimmun. Rev. 2013. 12:1070-5.</ns2:references>
    <ns2:rightsHolder>American Chemical
Society</ns2:rightsHolder>
    <ns2:references>Bruening, W., Giasson, B., Mushynski, W., Durham, H. D. Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter Nucleic Acids Res. 1998. 26:486-489.</ns2:references>
    <ns1:subject>HEK23T cells</ns1:subject>
    <ns1:subject>HEK-293T cells</ns1:subject>
    <ns2:references>Saxena, P., Bojar, D., Fussenegger, M. Design of Synthetic Promoters for Gene Circuits in Mammalian Cells Methods Mol. Biol. 2017. 1651:263-273.</ns2:references>
    <ns1:subject>enbrel</ns1:subject>
    <ns1:subject>human embryonic kidney cell line 293T</ns1:subject>
    <sbol:persistentIdentity rdf:resource="http://examples.org/sb8b00113"/>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00113_2_sequence/1"/>
    <ns2:isPartOf rdf:resource="http://pubs.acs.org/journal/asbcd6"/>
    <ns1:subject>I&#954;B</ns1:subject>
    <ns3:OBI_0002110 rdf:resource="https://doi.org/10.1021/acssynbio.8b00113"/>
    <ns1:subject>collagen</ns1:subject>
    <ns2:references>Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., Lim, W. A. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits Cell 2016. 164:770-9.</ns2:references>
    <ns1:subject>IKK2</ns1:subject>
    <ns1:subject>hTERT</ns1:subject>
    <ns2:references>Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J., Lim, W. A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor Science 2015. 350.</ns2:references>
    <ns2:references>Mertens, M., Singh, J. A. Anakinra for rheumatoid arthritis Cochrane Database Syst. Rev. 2009.</ns2:references>
    <ns1:subject>tGFP</ns1:subject>
    <ns2:references>Nan, J., Du, Y., Chen, X., Bai, Q., Wang, Y., Zhang, X., Zhu, N., Zhang, J., Hou, J., Wang, Q., Yang, J. TPCA-1 is a direct dual inhibitor of STAT3 and NF-&#954;B and regresses mutant EGFR-associated human non-small cell lung cancers Mol. Cancer Ther. 2014. 13:617-29.</ns2:references>
    <ns1:subject>I&#954;B&#945;</ns1:subject>
    <ns2:references>Kendall, S. D., Linardic, C. M., Adam, S. J., Counter, C. M. A network of genetic events sufficient to convert normal human cells to a tumorigenic state Cancer Res. 2005. 65:9824-8.</ns2:references>
    <ns2:references>Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., Bates, D. L., Guo, L., Han, A., Ziegler, S. F., Mathis, D., Benoist, C., Chen, L., Rao, A. FOXP3 controls regulatory T cell function through cooperation with NFAT Cell 2006. 126:375-87.</ns2:references>
    <ns2:references>Wurster, S. E., Maher, L. J. Selection and characterization of anti-NF-&#954;B p65 RNA aptamers RNA 2008. 14:1037-1047.</ns2:references>
    <ns2:references>Smole, A., Lainscek, D., Bezeljak, U., Horvat, S., Jerala, R. A synthetic mammalian therapeutic gene circuit for sensing and suppressing inflammation Mol. Ther. 2017. 25:102-119.</ns2:references>
    <ns1:subject>rec</ns1:subject>
    <ns1:subject>PEI</ns1:subject>
    <ns2:references>Ciceri, F., Bonini, C., Stanghellini, M. T., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., Pescarollo, A., Servida, P., Magnani, Z., Perna, S. K., Valtolina, V., Crippa, F., Callegaro, L., Spoldi, E., Crocchiolo, R., Fleischhauer, K., Ponzoni, M., Vago, L. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study Lancet Oncol. 2009. 10:489-500.</ns2:references>
    <ns1:subject>p65</ns1:subject>
    <ns2:references>Berger, J., Hauber, J., Hauber, R., Geiger, R., Cullen, B. R. Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells Gene 1988. 66:1-10.</ns2:references>
    <ns2:references>Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., Mease, P. J. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF&#173;{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases Ann. Rheum. Dis. 2005. 64:iv2-14.</ns2:references>
    <ns1:type>research-article</ns1:type>
    <sbol:version>1</sbol:version>
    <ns1:subject>T1452&#8211;1MG</ns1:subject>
    <ns2:references>Barrett, D. M., Teachey, D. T., Grupp, S. A. Toxicity management for patients receiving novel T-cell engaging therapies Curr. Opin. Pediatr. 2014. 26:43-49.</ns2:references>
    <ns1:subject>c-mycT58A</ns1:subject>
    <ns2:references>Zhang, J., Wang, X., Zhao, Y., Chen, B., Suo, G., Dai, J. Neoplastic transformation of human diploid fibroblasts after long-term serum starvation Cancer Lett. 2006. 243:101-8.</ns2:references>
    <ns1:subject>pNF&#954;B</ns1:subject>
    <sbol:displayId>sb8b00113</sbol:displayId>
    <ns1:subject>gene network</ns1:subject>
    <ns1:subject>CAR T-cells</ns1:subject>
    <ns1:subject>cytokine</ns1:subject>
    <ns1:subject>Na-alginate</ns1:subject>
    <ns1:subject>L2654</ns1:subject>
    <ns1:publisher>American
Chemical Society</ns1:publisher>
    <ns1:subject>Alginate</ns1:subject>
    <ns1:subject>TPCA-1</ns1:subject>
    <ns1:subject>polyinosinic-polycytidylic acid</ns1:subject>
    <ns1:subject>GFP FOXP3</ns1:subject>
    <ns1:subject>Neutralizer Cells</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/ComponentDefinition/sb8b00113_4_comp/1"/>
    <ns1:subject>CDK4R24C</ns1:subject>
    <ns1:subject>p53DD</ns1:subject>
    <ns1:subject>pp65</ns1:subject>
    <sbol:member rdf:resource="http://examples.org/Sequence/sb8b00113_4_sequence/1"/>
    <ns1:subject>aptamer</ns1:subject>
    <ns2:references>Caskey, M., Lefebvre, F., Filali-Mouhim, A., Cameron, M. J., Goulet, J. P., Haddad, E. K., Breton, G., Trumpfheller, C., Pollak, S., Shimeliovich, I., Duque-Alarcon, A., Pan, L., Nelkenbaum, A., Salazar, A. M., Schlesinger, S. J., Steinman, R. M., Se&#769;kaly, R. P. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans J. Exp. Med. 2011. 208:2357-66.</ns2:references>
    <ns1:subject>cat</ns1:subject>
    <ns2:created>2018-10-25</ns2:created>
    <ns2:references>Chabaud, M., Fossiez, F., Taupin, J. L., Miossec, P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines J. Immunol 1998. 161:409-14.</ns2:references>
    <ns1:subject>poly</ns1:subject>
    <ns1:subject>IgG1</ns1:subject>
    <ns1:subject>Secreted alkaline phosphatase</ns1:subject>
    <ns1:subject>EYFP</ns1:subject>
    <ns1:subject>HRasG12V</ns1:subject>
  </sbol:Collection>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00113_3_comp/1">
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00113_3_comp"/>
    <sbol:version>1</sbol:version>
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00113/suppl/sb-2018-00113a_si_001.pdf"/>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
    <sbol:displayId>sb8b00113_3_comp</sbol:displayId>
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00113"/>
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00113_3_sequence/1"/>
  </sbol:ComponentDefinition>
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00113_2_sequence/1">
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00113_2_sequence"/>
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
    <sbol:displayId>sb8b00113_2_sequence</sbol:displayId>
    <sbol:version>1</sbol:version>
    <sbol:elements>ttgacggctagcaaacaccggtgaacgaaactctgggagctgcgattggcagaattccgttagcaaggccgcaggacttgcagggagtatatgggcgcacttcggtgacggtacaggctccttgcttatcctgcggcgcgggcgcgtttcccggatcctgaaactgttttaaggttggccgatcgggttacgcgcccgccttaagtgtttctcgtagtgggtcgaattccgctcagagttggcacttaagcttgctaacggaattcccccatatccaacttccaatttaatctttcttttttaattttcacttatttgcgtttttttgaatctatccagcacagtggcggccgctcgagtctagagggc</sbol:elements>
  </sbol:Sequence>
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00113_4_sequence/1">
    <sbol:elements>agcgcggccgctcattagtctcctccagcgcctttg</sbol:elements>
    <sbol:displayId>sb8b00113_4_sequence</sbol:displayId>
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00113_4_sequence"/>
    <sbol:version>1</sbol:version>
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
  </sbol:Sequence>
  <sbol:ComponentDefinition rdf:about="http://examples.org/ComponentDefinition/sb8b00113_2_comp/1">
    <sbol:sequence rdf:resource="http://examples.org/Sequence/sb8b00113_2_sequence/1"/>
    <sbol:version>1</sbol:version>
    <sbol:persistentIdentity rdf:resource="http://examples.org/ComponentDefinition/sb8b00113_2_comp"/>
    <sbh:supplementalFile rdf:resource="file:///C:/Users/JVM/Downloads/sequence_supplementals/synbict_output/sb8b00113/suppl/sb-2018-00113a_si_001.pdf"/>
    <sbol:type rdf:resource="http://www.biopax.org/release/biopax-level3.owl#DnaRegion"/>
    <ns0:wasDerivedFrom rdf:resource="https://doi.org/10.1021/acssynbio.8b00113"/>
    <ns0:wasGeneratedBy rdf:resource="https://synbiohub.org/public/sbksactivities/ACS_Synbio_Generation/1"/>
    <sbol:displayId>sb8b00113_2_comp</sbol:displayId>
  </sbol:ComponentDefinition>
  <sbol:Sequence rdf:about="http://examples.org/Sequence/sb8b00113_3_sequence/1">
    <sbol:elements>agaagcttgccaccatggcgcccgtcgccgtctg</sbol:elements>
    <sbol:version>1</sbol:version>
    <sbol:persistentIdentity rdf:resource="http://examples.org/Sequence/sb8b00113_3_sequence"/>
    <sbol:displayId>sb8b00113_3_sequence</sbol:displayId>
    <sbol:encoding rdf:resource="http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html"/>
  </sbol:Sequence>
</rdf:RDF>
